The Impact of Amgen v. Sandoz

On March 13, 2015, the District Court for the Northern District of California (No. 14-cv-04741) will hear arguments as to whether the exchange of patent information under the Biologics Price Competition and Innovation Act (“BPCIA”) is mandatory, or whether biosimilar applicants can choose to opt out of the “Patent Dance” based on the level of certainty they want regarding patent infringement issues before they launch their products.

A decision is expected soon after the hearing, and Goodwin Procter partner Elaine Herrmann Blais, and associate Alexandra Lu will provide insight on the impact the case will have on the BPCIA regulatory pathway for biosimilars.

For further information, please visit: https://attendee.gotowebinar.com/register/1417006969921379841.